Research Paper Volume 13, Issue 10 pp 13663—13679
The lncRNA GATA3-AS1/miR-495-3p/CENPU axis predicts poor prognosis of breast cancer via the PLK1 signaling pathway
Figure 8. Expression and biological significance of the lncRNA GATA3-AS1 in breast carcinoma. (A) Expression levels of GATA3-AS1 in breast carcinoma as determined with GEPIA. (B) Expression levels of GATA3-AS1 in breast cancer as determined with the starBase database. (C) Prognostic value of GATA3-AS1 in breast cancer as determined with GEPIA. (D–F) Relative expression levels of GATA3-AS1, CENPU, and miR-495-3p in MDA-MB-468, BT-549, HCC1954, MCF-7, and MCF-10A cell lines as determined by qRT-PCR. (G) Western blotting analysis of CENPU protein levels in MCF-7 cells after the cells were transfected with sh-NC, sh-GATA3-AS1#1, sh-GATA3-AS1#2. (H) Quantitative RT-PCR analysis of miR-495-3p levels in MCF-7 cells after the cells were transfected with sh-NC, sh-GATA3-AS1#1, sh-GATA3-AS1#2. (I) Proliferation of MCF-7 cells after the cells were transfected with sh-NC, sh-GATA3-AS1#1, sh-GATA3-AS1#2 by MTT assay. (J) The identified lncRNA-miRNA-mRNA axis that can predict the prognosis of breast cancer patients. **P < 0.01, *P < 0.05.